Business

Following Pulmatrix's recent successful public offering, Pulmatrix and Cipla subsidiary Cipla Technologies (Cip Tec) have entered into a definitive agreement in which Cipla will acquire rights to the Pulmazole itraconazole DPI for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. The companies had previously announced terms of the … [Read more...] about Pulmatrix and Cip Tec enter into definitive agreement for Pulmazole

Cipla Limited has announced the launch of its Niveoli extra-fine particle beclomethasone/formoterol fumarate MDI for the treatment of asthma and COPD in adults in India. Cipla India Business Head Nikhil Chopra commented, “Cipla is pleased to offer yet another milestone in respiratory inhalation therapy. Niveoli marks a first in acknowledging and addressing the issue … [Read more...] about Cipla launches Niveoli MDI in India

Insmed Incorporated said that the U.S. Patent and Trademark Office (USPTO) has issued US patent No. 10,251,900, titled "Methods for treating pulmonary non-tuberculous mycobacterial infections," which is the 10th US patent covering the use of Arikayce amikacin liposome inhalation suspension for the treatment of Mycobacterium avium complex (MAC) lung disease. Arikayce … [Read more...] about Insmed gets additional US patent for Arikayce inhalation suspension

Noveome Biotherapeutics said that it has closed a $15 million Series D financing round that will help to fund further development of its ST266 biologic. Intranasal formulations of ST266 are in development for the treatment of optic nerve disease and for chronic traumatic encephalopathy (CTE). In 2017, Noveome announced positive data from a preclinical study of … [Read more...] about Noveome Biotherapeutics raises $15 million for development of ST266

Pulmatrix said that it has closed a public offering with expected gross proceeds of $16.6 million that will be used primarily for development of its inhaled therapies, especially Pulmazole inhaled itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. The company had previously said that it expected to raise $14.4 … [Read more...] about Pulmatrix raises $16.6 million in public offering

Endo International has announced that its subsidiary Endo Procurement Operations Limited recently reached an agreement with Merck to distribute an authorized generic of Proventil HFA albuterol sulfate MDI in the US. Endo operating company Par Pharmaceutical has already started shipping the inhaler, the company said. 3M Drug Delivery Systems manufactures Proventil … [Read more...] about Par Pharmaceutical launches authorized generic of Proventil HFA in US

Opiant Pharmaceuticals has received an additional $3 million from a 3-year grant awarded in 2018 by the National Institutes of Health’s (“NIH”) National Institute on Drug Abuse (“NIDA”) to support development of OPNT003 intranasal nalmefene for the treatment of opioid overdose. The company previously received $2.6 million from the grant, which is worth up to a total … [Read more...] about Opiant Pharmaceuticals gets additional funding for intranasal nalmefene

MannKind Corporation has announced that it has received a $12.5 million milestone payment from United Therapeutics for the first milestone related to development of a treprostinil Technosphere (TreT) DPI for the treatment of pulmonary arterial hypertension. The company did not specify what milestone had been achieved. United Therapeutics and MannKind announced the … [Read more...] about MannKind gets first milestone payment from United Therapeutics for treprostinil DPI development